OPEN END INDEX-CERTIFICATE - AMGEN Stock

Certificat

8F99S

FRSGE001LDE4

Real-time Euronext Paris 08:34:34 2024-05-30 pm EDT
0.91 ^EUR	0.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Chart OPEN END INDEX-CERTIFICATE - AMGEN

Latest news about AMGEN INC.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	May. 28	RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval	May. 28	DJ
Weight-loss drug forecasts jump to $150 billion as supply grows	May. 28	RE
Supreme Court Holds Invalid Cholesterol Drug Patent That Covered Millions Of Undisclosed Antibodies	May. 27	AQ

More news

Static data

Product type	Index- and Participation Certificates
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
	8F99S
ISIN	FRSGE001LDE4
Date issued	2023-04-25
Maturity	Unlimited
Parity	1 : 1
Emission price	0.91 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company